<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01353690</url>
  </required_header>
  <id_info>
    <org_study_id>10-013</org_study_id>
    <nct_id>NCT01353690</nct_id>
  </id_info>
  <brief_title>Autologous Cell Therapy for Ischemic Heart Failure</brief_title>
  <official_title>A Prospective, Multicenter, Feasibility Study of Autologous Muscle-derived Cell (AMDC) Transplantation for Treatment of Advanced Ischemic Heart Failure</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cook MyoSite</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cook MyoSite</source>
  <brief_summary>
    <textblock>
      The aim of this clinical study is to investigate the safety and feasibility of Autologous&#xD;
      Muscle-derived Cells (AMDC; a preparation of a patient's own cells) as a treatment for&#xD;
      patients with advanced heart failure caused by ischemia.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <start_date type="Actual">February 5, 2011</start_date>
  <completion_date type="Actual">June 2014</completion_date>
  <primary_completion_date type="Actual">December 12, 2012</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of major adverse events associated with the use of AMDC</measure>
    <time_frame>12 Months</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">9</enrollment>
  <condition>Ischemic Heart Disease</condition>
  <arm_group>
    <arm_group_label>AMDC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>AMDC</intervention_name>
    <description>Cell Treatment</description>
    <arm_group_label>AMDC</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age greater than 18 but less than 80 years&#xD;
&#xD;
          -  Prior myocardial infarction&#xD;
&#xD;
          -  Depressed left ventricular ejection fraction (LVEF) ≤ 35%&#xD;
&#xD;
          -  NYHA functional classification of II to IV&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Not under stable optimal medical management&#xD;
&#xD;
          -  Cardiac surgery or percutaneous coronary intervention within 3 months&#xD;
&#xD;
          -  Occurrence of myocardial infarction (MI) within 6 months, in the case of first MI, or&#xD;
             3 months, in the case of any subsequent MI&#xD;
&#xD;
          -  Prior cell, gene, or transmyocardial laser revascularization therapy&#xD;
&#xD;
          -  Ventricular wall thickness in target region ≤ 5 mm&#xD;
&#xD;
          -  Moderate to severe aortic valve stenosis or mechanical valve replacement&#xD;
&#xD;
          -  Left ventricular aneurysm or thrombus&#xD;
&#xD;
          -  Left ventricular dysfunction associated with a reversible cause&#xD;
&#xD;
          -  Vascular disease preventing percutaneous vascular access&#xD;
&#xD;
          -  History of myopathic disease&#xD;
&#xD;
          -  History of neoplasia within 5 years, except for basal cell carcinoma&#xD;
&#xD;
          -  Receiving or planning to receive anti-cancer medications&#xD;
&#xD;
          -  Serum creatinine &gt; 3.0 mg/dl&#xD;
&#xD;
          -  Pregnant, planning to become pregnant, or breastfeeding a child in the next 18 months&#xD;
&#xD;
          -  Life expectancy of less than 1 year&#xD;
&#xD;
          -  Morbid obesity (defined as BMI &gt; 35)&#xD;
&#xD;
          -  History of bleeding diathesis or coagulopathy&#xD;
&#xD;
          -  Positive for HIV, Hepatitis B, or Hepatitis C&#xD;
&#xD;
          -  Known hypersensitivity or contraindication to study product or treatment procedure&#xD;
&#xD;
          -  Enrolled in another research project at the time of enrollment&#xD;
&#xD;
          -  Unable to provide informed consent&#xD;
&#xD;
          -  Unable or unwilling to commit to the follow-up clinical procedures&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hung Q. Ly, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Montreal Heart Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Alberta and Mazankowski Alberta Heart Institute</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T6G 2B7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Montreal Heart Institute</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H1T 1C8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>May 12, 2011</study_first_submitted>
  <study_first_submitted_qc>May 12, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 16, 2011</study_first_posted>
  <last_update_submitted>June 29, 2021</last_update_submitted>
  <last_update_submitted_qc>June 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cell Therapy</keyword>
  <keyword>Heart Failure</keyword>
  <keyword>Heart Disease</keyword>
  <keyword>Myocardial Infarction</keyword>
  <keyword>Myocardial Ischemia</keyword>
  <keyword>Autologous</keyword>
  <keyword>Muscle-derived Cell</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
    <mesh_term>Heart Diseases</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Ischemia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

